

Published by
Ministry of Health, Labour and Welfare



Translated by
Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions

Posaconazole

July 20, 2022

Therapeutic category

Antibiotic preparations acting mainly on mold

Non-proprietary name

Posaconazole

Safety measure

Precautions should be revised.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Revision in line with the Instructions for Electronic Package Inserts of Prescription Drugs, etc. PSEHB Notification No. 0611-1 by the Director of Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated June 11, 2021 (New instructions): Revised language is underlined.

Current	Revision							
<p>2. CONTRAINDICATIONS</p> <p>Patients receiving ergotamine tartrate/anhydrous caffeine/ isopropylantipyrine, dihydroergotamine, methylergometrine, ergometrine, simvastatin, atorvastatin, pimozide, quinidine, venetoclax [during its dose escalation phase for relapsed or refractory chronic lymphocytic leukemia (including small lymphocytic lymphoma)], suvorexant, lurasidone hydrochloride, or blonanserin</p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration</p> <p>(N/A)</p>	<p>2. CONTRAINDICATIONS</p> <p>Patients receiving ergotamine tartrate/anhydrous caffeine/ isopropylantipyrine, dihydroergotamine, methylergometrine, ergometrine, simvastatin, atorvastatin, pimozide, quinidine, venetoclax [during its dose escalation phase for relapsed or refractory chronic lymphocytic leukemia (including small lymphocytic lymphoma)], suvorexant, lurasidone hydrochloride, blonanserin, <u>or triazolam</u></p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration</p> <table border="1" data-bbox="1131 831 1964 1262"> <thead> <tr> <th data-bbox="1131 831 1408 917">Drugs</th> <th data-bbox="1411 831 1688 917">Signs, Symptoms, and Treatment</th> <th data-bbox="1691 831 1964 917">Mechanism and Risk Factors</th> </tr> </thead> <tbody> <tr> <td data-bbox="1131 919 1408 1262"><u>Triazolam</u></td> <td data-bbox="1411 919 1688 1262"><u>The effects of triazolam may be enhanced, and the duration of effects may be prolonged.</u></td> <td data-bbox="1691 919 1964 1262"><u>The blood concentration of triazolam is expected to rise due to inhibition of CYP3A4 by co-administration with posaconazole.</u></td> </tr> </tbody> </table>		Drugs	Signs, Symptoms, and Treatment	Mechanism and Risk Factors	<u>Triazolam</u>	<u>The effects of triazolam may be enhanced, and the duration of effects may be prolonged.</u>	<u>The blood concentration of triazolam is expected to rise due to inhibition of CYP3A4 by co-administration with posaconazole.</u>
Drugs	Signs, Symptoms, and Treatment	Mechanism and Risk Factors						
<u>Triazolam</u>	<u>The effects of triazolam may be enhanced, and the duration of effects may be prolonged.</u>	<u>The blood concentration of triazolam is expected to rise due to inhibition of CYP3A4 by co-administration with posaconazole.</u>						

N/A: Not Applicable. No corresponding language is included in the current Precautions.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp